Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

TBCRC 023: A Randomized Multicenter Phase II Neoadjuvant Trial of Lapatinib Pus Trastuzumab, With or Without Endocrine Therapy for 12 Weeks vs. 24 Weeks in Patients With HER2 Overexpressing Breast Cancer

NCT00999804 is registered in ClinicalTrials.gov with Baylor Breast Care Center as lead sponsor.

NCT NCT00999804
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00999804 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
TBCRC 023: A Randomized Multicenter Phase II Neoadjuvant Trial of Lapatinib Pus Trastuzumab, With or Without Endocrine Therapy for 12 Weeks vs. 24 Weeks in Patients With HER2 Overexpressing Breast Cancer
Lead sponsor
Baylor Breast Care Center
Phase
Phase 2
Overall status
Active, not recruiting
Start date
October 31, 2011
Completion date
January 31, 2026
Enrollment
128 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer